Remnant cholesterol and atherosclerotic disease in high cardiovascular risk patients. Beyond LDL cholesterol and hypolipidemic treatment

Roth, 2020, Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study, J Am Coll Cardiol, 76, 2982, 10.1016/j.jacc.2020.11.010 Matsuura, 2019, Highlighting residual atherosclerotic cardiovascular disease risk, Arterioscler Thromb Vasc Biol, 39, e1, 10.1161/ATVBAHA.118.311999 Patel, 2018, Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine, Circulation, 137, 2551, 10.1161/CIRCULATIONAHA.118.035289 Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease, J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026 Castañer, 2020, Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease, J Am Coll Cardiol, 76, 2712, 10.1016/j.jacc.2020.10.008 Varbo, 2013, Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation, Circulation, 128, 1298, 10.1161/CIRCULATIONAHA.113.003008 Jørgensen, 2013, Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, Eur Heart J, 34, 1826, 10.1093/eurheartj/ehs431 Baber, 2015, Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study, J Am Coll Cardiol, 65, 1065, 10.1016/j.jacc.2015.01.017 Sillesen, 2018, Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans, Eur Heart J Cardiovasc Imaging, 19, 1042, 10.1093/ehjci/jex239 Mach, 2020, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J, 41, 111, 10.1093/eurheartj/ehz455 Willeit, 2020, Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100 667 patients, Circulation, 142, 621, 10.1161/CIRCULATIONAHA.120.046361 Stamatelopoulos, 2021, Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19, Sci Rep, 11, 10.1038/s41598-021-99050-0 Panagiotakos, 2007, Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project), Hellenic J Cardiol, 48, 55 Lambrinoudaki, 2020, Circulating amyloid beta 1-40 is associated with increased rate of progression of atherosclerosis in menopause: a prospective cohort study, Thromb Haemostasis Touboul, 2012, Cerebrovasc Dis (Basel, Switzerland), 34, 290, 10.1159/000343145 Amato, 2017, Carotid plaque-thickness and common carotid IMT show additive value in cardiovascular risk prediction and reclassification, Atherosclerosis, 263, 412, 10.1016/j.atherosclerosis.2017.05.023 Baldassarre, 2012, J Am Coll Cardiol, 60, 1489, 10.1016/j.jacc.2012.06.034 Baber, 2015, Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage Study, J Am Coll Cardiol, 65, 1065, 10.1016/j.jacc.2015.01.017 Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal Disease Study Group, Ann Intern Med, 130, 461, 10.7326/0003-4819-130-6-199903160-00002 2022, 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022, Diabetes Care, 45, S17 Grundy, 2019, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines, J Am Coll Cardiol, 73, e285, 10.1016/j.jacc.2018.11.003 Nordestgaard, 1995, Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media, Arterioscler Thromb Vasc Biol, 15, 534, 10.1161/01.ATV.15.4.534 Shaikh, 1991, Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans, Arterioscler Thromb, 11, 569, 10.1161/01.ATV.11.3.569 Nordestgaard, 2016, Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology, Circ Res, 118, 547, 10.1161/CIRCRESAHA.115.306249 Reiner, 2019, The year in cardiology 2018: prevention, Eur Heart J, 40, 336, 10.1093/eurheartj/ehy894 Elshazly, 2020, Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease, Eur J Prev Cardiol, 27, 1091, 10.1177/2047487319887578 Qian, 2021, Remnant cholesterol and common carotid artery intima-media thickness in patients with ischemic stroke, Circ Cardiovasc Imag, 14, 10.1161/CIRCIMAGING.120.010953 Lin, 2019, Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography, Atherosclerosis, 284, 24, 10.1016/j.atherosclerosis.2019.02.019 Quispe, 2021, Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study, Eur Heart J, 42, 4324, 10.1093/eurheartj/ehab432 Cao, 2020, The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes, Cardiovasc Diabetol, 19, 104, 10.1186/s12933-020-01076-7 Vallejo-Vaz, 2018, Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT Trial, Circulation, 138, 770, 10.1161/CIRCULATIONAHA.117.032318 Nordestgaard, 2021, Triglyceride-rich lipoprotein cholesterol (Remnant Cholesterol) as a therapeutic target for cardiovascular disease risk, 139 Nordestgaard, 2018, Advances in lipid-lowering therapy through gene-silencing technologies, Nat Rev Cardiol, 15, 261, 10.1038/nrcardio.2018.3